Keyphrases
Chronic Myeloid Leukemia
73%
Tumor
54%
Acute Myeloid Leukemia
39%
T Cells
39%
T-cell Lymphoma
36%
Mycosis Fungoides
30%
Chronic Lymphocytic Leukemia
28%
Leukemia
25%
Peripheral T-cell Lymphoma
25%
Lymphoma
25%
B Cells
24%
Molecular Diagnostics
23%
Cutaneous T-cell Lymphoma
22%
COVID-19
22%
Imatinib
22%
Tyrosine Kinase Inhibitor
21%
Epstein-Barr Virus
21%
Imatinib Mesylate
21%
Peripheral Blood
19%
Bone Marrow
19%
Lymph Node
19%
Chemotherapy
18%
Chronic Phase
18%
Acute Lymphoblastic Leukemia
17%
Phase II Study
17%
BCR-ABL mutations
17%
Diffuse Large B-cell Lymphoma (DLBCL)
16%
Tumor Cells
16%
Philadelphia Chromosome
16%
Herpesvirus
15%
Follicular Lymphoma
15%
Quantitative PCR
15%
Neoplasms
15%
Anaplastic Large Cell Lymphoma
15%
Marek's Disease Virus
14%
FMS-like Tyrosine Kinase 3 (FLT3)
13%
Cell Tumor
13%
Dasatinib
13%
Lymphoma Cells
13%
CD30
12%
BCR-ABL
12%
Fluorescence in Situ Hybridization
12%
Ibrutinib
12%
CD4+
12%
Immunophenotyping
12%
Non-Hodgkin Lymphoma
12%
Germinal Center
11%
Myelodysplastic Syndrome
11%
Acute Promyelocytic Leukemia
11%
T-cell Leukemia
11%
Medicine and Dentistry
Neoplasm
100%
Disease
47%
T Cell
47%
B Cell
43%
Chronic Myelogenous Leukemia
40%
T-Cell Lymphoma
33%
Acute Myeloid Leukemia
32%
Mycosis fungoides
27%
B-Cell Chronic Lymphocytic Leukemia
24%
Cutaneous T Cell Lymphoma
23%
Imatinib
22%
Peripheral T-Cell Lymphoma
21%
Non-Hodgkin Lymphoma
21%
Chemotherapy
20%
Epstein Barr Virus
20%
Leukemia
18%
Phosphotransferase
18%
Hodgkin's Lymphoma
17%
Lymphocyte
17%
Tyrosine-Kinase Inhibitor
17%
Lymph Node
17%
Acute Lymphoblastic Leukemia
16%
Morphology
16%
Malignant Neoplasm
16%
Philadelphia 1 Chromosome
16%
Adult T-Cell Leukemia/Lymphoma
16%
Follicular Lymphoma
15%
Diagnosis
15%
Diffuse Large B-Cell Lymphoma
15%
Immunophenotyping
14%
Anaplastic Large Cell Lymphoma
14%
B-Cell Lymphoma
14%
Precursor
14%
Tumor Cell
13%
Lymphoproliferative Disease
13%
Cancer
13%
Next Generation Sequencing
13%
Dasatinib
12%
Fluorescence in Situ Hybridization
12%
Germinal Center
12%
Overall Survival
12%
Radiation Therapy
12%
Angiofollicular Lymph Node Hyperplasia
12%
Ibrutinib
11%
Molecular Pathology
11%
Biopsy Technique
11%
T Lymphocyte Receptor
11%
Molecular Diagnostics
11%
Immunohistochemistry
10%
Myelodysplastic Syndrome
10%